Teriparatide Purity: 4 Lab Tests Across 2 Identified Manufacturers
1 study on Teriparatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently tracks 4 published third-party lab tests of Teriparatide across 2 identified manufacturers. Among reports with a positive numeric purity result, the average is 97.23%. Within this published corpus, 0 positive purity results were below 90%, and 0 reports showed measured quantity more than 10% below the label claim. These are batch-level observations, not guarantees of product identity, safety, or vendor quality.
Teriparatide average prices
As of 2026-09-04, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 750 mcg | $13.00 | $13.00–$13.00 | $17.33 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. The refresh date is the catalog build date; individual source observation dates are not available in this snapshot. View full price methodology →
We tested 4 Teriparatide batches across 2 identified manufacturers
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
Top 3 vendor evidence profiles for Teriparatide
Eligible vendors have at least 2 deduplicated tests and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and test count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes tested batches, not every product or shipment, and is not an endorsement.
| Rank | Manufacturer | Tests | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 3 | 97.09% | 0 of 3 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Manufacturer identities are included with Pro. Batch counts and lab measurements remain visible.
Recent certificates: #91909 (92.675%) · #71013 (99.205%) · #25889 (97.635%) · #70760 (99.39%)
Teriparatide studies and clinical research
-
Long-Term PTH(1-34) Therapy for Hypoparathyroidism May Overstimulate Bone
This study highlights the critical need for careful monitoring of bone health in patients on long-term PTH(1-34) therapy for hypoparathyroidism. The findings suggest that while effective in managing calcium levels, pr…
Research tools
Free, no account — handy when you're working with Teriparatide.
